Dahse, Regine and Driemel, Oliver and Schwarz, Stephan and Kromeyer-Hauschild, Katrin and Berndt, Alexander and Kosmehl, Hartwig (2009) KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. ORAL ONCOLOGY, 45 (9). pp. 826-829. ISSN 1368-8375,
Full text not available from this repository. (Request a copy)Abstract
Salivary gland carcinomas (SGC) are rare cancers with poor prognosis and limited response to conventional chemotherapy. New strategies based on molecular targeted therapy are needed and the EGFR signaling cascade is considered a possible key pathway for therapeutic molecules. We have analyzed 65 SGC of the main histopathological types for the expression of EGFR and and the mutation status of its downstream effector KRAS. EGFR overexpression (+2, +3) has been identified by immunohistochemistry in 75.4%. KRAS mutation analysis was performed by direct genomic sequencing and revealed a KRAS wildtype in 98.5% except of one adenoid cystic carcinoma with a GGT-GAT transition at codon 12 (Gly12Asp). EGFR overexpression and KRAS wildtype are prerequisites for a successful anti-EGFR therapy. The results of this study plead in favor of further therapeutic trials with EGFR-targeting monoclonal antibodies in SGC. (c) 2009 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CELL LUNG-CANCER; PHASE-II TRIAL; COLORECTAL-CANCER; ONCOLOGY-GROUP; ADVANCED HEAD; MUTATIONS; GEFITINIB; GENE; CHEMOTHERAPY; ERLOTINIB; Epidermal growth factor receptor; KRAS; Mutation screening; Salivary gland carcinomas; EGFR-targeted therapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Mund-, Kiefer- und Gesichtschirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 09 Sep 2020 06:51 |
| Last Modified: | 09 Sep 2020 06:51 |
| URI: | https://pred.uni-regensburg.de/id/eprint/28526 |
Actions (login required)
 |
View Item |
